Navigation Links
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
Date:5/29/2009

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) breast cancer, and a separate study investigating neratinib safety and efficacy when given with paclitaxel (Taxol(R), Bristol-Myers Squibb) in patients with HER-2 dependent solid tumors. The data gathered from both trials are scheduled to be presented at the 45th Annual Meeting of the American Society of Clinical Oncology Annual Meeting in Orlando, Florida, from May 29 to June 2, 2009. Neratinib is an investigational orally administered irreversible inhibitor of the HER-2 and EGFR kinases.

"The data gathered from these studies provide additional evidence suggesting that neratinib, when combined with these therapies, is an active agent in HER-2 positive breast cancer," says Ramona Swaby, M.D., Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA. "While improvements have been made in treating HER-2 positive breast cancer, there remains an unmet medical need for more therapies for patients with metastatic breast cancer. These data warrant ongoing and future investigations to further understand and evaluate the utility of neratinib against this aggressive disease."

Neratinib (HKI-272) in Combination with Trastuzumab for the Treatment of Advanced Breast Cancer

This ongoing phase 1/2 study of neratinib in combination with trastuzumab evaluated patients with advanced ErbB-2 positive breast cancer that progressed following therapy with trastuzumab, the standard of care in this disease setting. The primary endpoint of the two-part study is 16-week progression-free survival (PFS). The first part of
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
2. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
3. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
4. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
5. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
6. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
7. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
10. What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., BOTHELL, Wash., Dec. 1 ...hat on November 20, 2009 it licensed to Chrono Nut...facture and sell four extended release dietary sup...delivery platform. In addition, SCOLR granted Chr...ducts in the United States on a nonexclusive basis...
(Date:12/1/2009)...LEN BURNIE, Md., Dec. 1 Sleep Solu...rvice provider for home testing and evaluation of ... named Richard Hassett, M.D., as its chief executi...f Matria Healthcare, during its growth from a $250...llion industry leader in total population health, ...
(Date:12/1/2009)... , TAI,AN, China, Dec. 1 /PRNewswire-Asia...Bulletin Board: CBPO) (Nasdaq: CBPO ) ("China Bio...ma-based biopharmaceutical companies in,China, tod...l to list its,common stock on the NASDAQ Global Ma... to begin trading on the NASDAQ on,Wednesday, Dece...
Breaking Medicine Technology:SCOLR Pharma, Inc. Licenses Dietary Supplements 2SCOLR Pharma, Inc. Licenses Dietary Supplements 3Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3China Biologic Products Approved to List on NASDAQ 2China Biologic Products Approved to List on NASDAQ 3US Oncology Inc Announces 24465 Million Senior Secured Notes Offering 47879 1US Oncology Inc Announces 24465 Million Senior Secured Notes Offering 47879 2DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares 47877 1DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares 47877 2DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares 47877 3DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares 47877 4Xceed Meets HTX CIHR Grant Milestone 3A Decreasing Sample Prep Time From Days to Less Than Eight Hours 12464 1Xceed Meets HTX CIHR Grant Milestone 3A Decreasing Sample Prep Time From Days to Less Than Eight Hours 12464 2
...ence Call to be Held at 9:00 a.m. Eastern Time Tod...United Therapeutics Corporation (Nasdaq: UTHR ) ...ug Administration (FDA) has approved ADCIRCA(TM) (... recommended dose of 40 mg, as the first once-dail...e treatment of pulmonary arterial hypertension (PA...
...LIS, Md., May 22 PharmAthene, Inc. (NYSE Amex: ...ountermeasures against biological and chemical thr...ed its comprehensive regulatory strategy to the U....e non-clinical and clinical development plans for ...inant protective antigen anthrax vaccine. , , The...
Other Medicine Technology:FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 2FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 3FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 4PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA 2PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA 3PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA 4
(Date:12/1/2009)... CDC urges H1N1 vaccination because pandemic,s cou...ec. 1 (HealthDay News) -- A U.S. health official s...to be on the wane nationally, but many experts agr...ter. , The flu is now widespread in 32 states -...R. Frieden, director of the U.S. Centers for Disea...
(Date:12/1/2009)..., , RESEARCH TRIANGLE PARK, N.C., Dec....re initiated in 2001 and have expanded over the ye...globally. The facility which was originally set up...e. Pharmacy services, as part of the suite of serv...harma industry as a valuable offering. ,, The p...
(Date:12/1/2009)..., , WASHINGTON, Dec. 1 /PRNewswire-USNewsw.... Agency for International Development: ,, Chai...he Committee. ,, I am honored to be nominated b... United States Agency for International Developmen...he Agency. ,, Secretary of State Clinton has e...
(Date:12/1/2009)..., (December 1, 2009) The ADEAGies Foundation wil...Achievement Award at the Gies Awards celebration t... in conjunction with the 2010 ADEA Annual Session ...n, Innovation, and Achievement recognize contribut...cation initiatives. For a complete listing of Gies...
(Date:12/1/2009)... Stronger cardiovascular system tied to academic a....1 (HealthDay News) -- A strong cardiovascular sys...g for better school grades and more overall succes... that most doctors and laypeople know (or should k...althy bodies, the authors of a new study, appearin...
Breaking Medicine News(10 mins):Health News:Swine Flu Waning, But Could Return 2Health News:Swine Flu Waning, But Could Return 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 2Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 4Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 5Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 6Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 7Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 8Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 9Health News:The Forsyth Institute receives the William J. Gies Award for outstanding achievement 2Health News:Exercise May Lead to a Smarter, More Successful You 2Health News:Exercise May Lead to a Smarter, More Successful You 3
...ad Public Policy, WASHINGTON, Sept. 27 - A ground...rn Reserve University professors Max,Mehlman and D...some,prohibitively expensive and would come at the...lth courts would require,the creation of new and c...
...evelopment, Highlight, Professional Development O...NCINNATI, Sept. 27 Kendle (Nasdaq: KNDL ), a,lea...zation, today,announced that Vice President, Globa...n Friday, Sept. 28 at 9 a.m. The,presentation, tit...
...ers, and Weiner, ALEXANDRIA, Va., Sept. 27 The N...oday applauds the official launch,of the bipartisa...Coalition,s primary objective is to preserve patie...ide in underserved,rural and urban communities. "...
...n Pharma,Limited, a specialty pharmaceutical compa...etary products in secondary healthcare and related...e marketing and,distribution rights to DepoDur(R) ... http://www.newscom.com/cgi-bin/prnh/20070618/PACI...
...aq: PRGO ; TASE) announced today that it had file...uaifenesin Extended-Release Tablets, 600 mg, a,gen...extended-release tablets, 600 mg), an expectorant,...rs for the 12 months ended August 2007, as measure...
...p Consumers Measure Their ...he creators of,the "Life ... supplemented" campaig...Wells, Wells, WannabeWells or OhWells. With the la...re their,wellness regimen and determine where they...
Other Medicine News:Health News:New Report Says 'Health Courts' Bureaucracies Offer Big Financial Burdens and Loss of Patient Rights 2Health News:Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007 2Health News:Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007 3Health News:Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007 4Health News:Congressional Community Pharmacy Coalition To Protect Community Pharmacies and Preserve Patient Access 2Health News:Congressional Community Pharmacy Coalition To Protect Community Pharmacies and Preserve Patient Access 3Health News:Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe 2Health News:Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe 3Health News:Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory 2Health News:Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory 3Health News:Are You An AlphaWell or An OhWell? 2
... Web-based and RFID-enabled location system that a...ow and utilization of resources throughout the per...gileTrac collects patient information including lo... might experience. This information is directed to...
RoamAlert Eco
awarix Enterprise Visibility Solutions for Healthcare
Radianse Indoor Positioning Patient Location
Medicine Products: